Latest news with #Levodopa
Winnipeg Free Press
a day ago
- Health
- Winnipeg Free Press
Missed visit ‘can be a life and death thing'
The DAUGHTER of a woman living in a Winnipeg assisted-living facility is raising concerns after a mixup at home care's new centralized scheduling office nearly caused her mother to miss essential medication. Koralee Nickarz, who lives in Vancouver but returns to Winnipeg every six weeks to visit her mother, 82-year-old Paulette Nickarz, said that had she not been in town last week, her mother would have missed critical nighttime medications. Her mother's regular bedtime worker didn't show up, and no replacement had been arranged. Nickarz said she had to call home care's after-hours line to find out if a worker was still coming. She eventually learned that the scheduled aide had left to tend to a family emergency. JOHN WOODS / FREE PRESS Koralee Nickarz, with her mother Paulette, is concerned centralized scheduling is putting her mom's life in danger. 'No one knew because the home-care worker could not get through to the scheduling office. And she didn't have the time to wait on hold.' Nickarz said a customer service representative later told her that some aides had waited up to five hours on hold or for a callback that same day. 'Before moving to the centralized office, scheduling used to call me when they did not have a worker,' Nickarz said. 'Now, no worker shows up. Or they send someone at whatever time they can find someone for my mother's timed medication.' The Winnipeg Regional Health Authority centralized its home-care scheduling operations in late March, at a single location on Sutherland Avenue. The move was intended to address issues with communication, service inconsistency and workload. In a Jan. 23 memo introducing the changes, the WRHA said the move was also prompted by a review following the 2023 death of cancer patient Katherine Ellis who died after being misclassified and denied timely care. At the time, nurses described the rollout as rushed and chaotic, saying it disrupted care and overwhelmed staff. Some reported insulin-dependent clients had gone hours without medication, while others noted overlapping shifts or being dispatched to unfamiliar areas, causing further delays and cancellations. Nickarz said health-care aides she's spoken to have described the new system as a 'shit show.' She fears the consequences of delayed care for her mother, who has Parkinson's and requires medication at strict intervals. 'She has to take her Levodopa… every four hours,' Nickarz said. 'If she doesn't get it on time, she has a really hard time walking. And if she gets up, it's likely that she will fall. If she gets her Levodopa less than four hours apart, it can cause nausea, dizziness and confusion, which makes it more likely she could fall.' Her mother receives eight visits per day, including four for medication. Under the previous system, Nickarz said she would receive notice of care disruption a few days in advance. Now, she said, no one informs her if no one is coming — and staff at the assisted-living facility are not permitted to administer medications. A WRHA spokesperson said last week that the centralized scheduling office continues to improve service for both clients and staff. They noted that the average wait time for staff calling the office is currently 9 minutes and 20 seconds. Weekday Mornings A quick glance at the news for the upcoming day. 'We recognize there are periods when wait times may be longer, and we remain committed to reducing them,' the spokesperson said. They also pointed to recent changes, including new escalation pathways for urgent issues, a voicemail system for staff unable to work, and a pilot system to fill open shifts more efficiently. 'When changes to a client's schedule are necessary due to staffing, the scheduling office will reach out to the client or their primary contact to ensure they are informed and that backup care plans are in place,' the spokesperson said. Nickarz remains skeptical. 'It can be a life and death thing, because we know what happens with seniors when they fall — they can die,' she said. Scott BilleckReporter Scott Billeck is a general assignment reporter for the Free Press. A Creative Communications graduate from Red River College, Scott has more than a decade's worth of experience covering hockey, football and global pandemics. He joined the Free Press in 2024. Read more about Scott. Every piece of reporting Scott produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates. Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Hans India
4 days ago
- Health
- Hans India
New weekly injection to offer steady Parkinson's medication, cut need for daily pills
A team of scientists in Australia, led by those of Indian origin, has developed a new once-a-week injectable drug that could transform the lives of more than eight million people living with Parkinson's disease, potentially replacing the need for multiple daily tablets. Frequent dosing is a burden, especially for elderly patients or those with swallowing difficulties, leading to inconsistent medication levels, more side effects, and reduced effectiveness. To address this, the team from the University of South Australia (UniSA) developed a long-acting injectable formulation that delivers a steady dose of levodopa and carbidopa -- two key medications for Parkinson's -- over an entire week. The biodegradable formulation is injected under the skin or into muscle tissue, where it gradually releases the medication over seven days, noted the researchers in the paper published in the journal Drug Delivery and Translational Research. The newly developed injectable could significantly improve treatment outcomes and patient adherence, said lead researcher Professor Sanjay Garg, from UniSA's Center for Pharmaceutical Innovation. "Our goal was to create a formulation that simplifies treatment, improves patient compliance, and maintains consistent therapeutic levels of medication. This weekly injection could be a game-changer for Parkinson's care," Garg said. "Levodopa is the gold-standard therapy for Parkinson's, but its short lifespan means it must be taken several times a day." The injectable gel combines a US FDA-approved biodegradable polymer, PLGA, with Eudragit L-100, a pH-sensitive polymer, to achieve a controlled and sustained drug release. The team noted that the release of both levodopa and carbidopa steadily over a week could help maintain consistent plasma levels and reduce the risks associated with fluctuating drug concentrations. Extensive lab tests confirmed the system's effectiveness and safety. More than 90 per cent of the levodopa dose and more than 81 per cent of the carbidopa dose were released over seven days. Notably, the implant degraded by over 80 per cent within a week and showed no significant toxicity in cell viability tests. In addition, the formulation can be easily administered through a fine 22-gauge needle, minimising discomfort and eliminating the need for surgical implantation. Garg said the technology could also be adapted for other chronic conditions such as cancer, diabetes, neurodegenerative disorders, pain management, and chronic infections that require long-term drug delivery.
Time Business News
24-06-2025
- Health
- Time Business News
How Specialized Parkinson's Home Care Improves Daily Living
Parkinson's disease is a progressive neurological condition that affects movement, balance, and coordination. As the disease advances, daily activities that once felt routine—such as walking, eating, or getting dressed—can become difficult and even dangerous. While family members often try to help, the increasing demands of care may require professional support. Specialized home care tailored for individuals with Parkinson's offers critical physical, emotional, and cognitive assistance, helping improve daily living and quality of life. In this article, we'll explore how Parkinson's home care works, its benefits, and how trusted providers like Visiting Angels Manassas support families across Prince William County and surrounding areas. Parkinson's disease primarily affects motor function, resulting in symptoms such as tremors, muscle stiffness, slowness of movement (bradykinesia), and impaired balance. These symptoms often interfere with simple daily tasks like writing, using utensils, or getting out of a chair. As the condition progresses, walking becomes more difficult and falls more likely. However, Parkinson's is not just a physical condition. Non-motor symptoms such as depression, sleep disturbances, fatigue, and cognitive decline can be just as challenging. Over time, these symptoms can diminish confidence and increase dependency on others for daily support. This combination of physical and emotional impact often leads families to seek long-term solutions that maintain safety and well-being at home. One of the most significant benefits of specialized home care is assistance with mobility and physical safety. Individuals with Parkinson's often experience unsteadiness, slower reflexes, and difficulties with balance. This greatly increases the risk of falls, which can lead to serious injuries. Professional caregivers trained in Parkinson's care know how to assist with transferring from bed to chair, walking around the house, and using assistive devices properly. They are also skilled in spotting mobility-related hazards and suggesting modifications like grab bars, shower benches, or the removal of clutter. For families seeking Parkinson's care in Manassas these services provide critical support in maintaining independence while minimizing physical risks. Proper medication management is vital for those living with Parkinson's. Medications like Levodopa must be taken at specific times to manage symptoms effectively. A missed or late dose can quickly result in loss of motor control or increased stiffness. Home caregivers ensure medications are taken on schedule and watch for any adverse effects or symptom changes. They also assist with daily routines such as eating, bathing, grooming, and dressing, tasks that become more complex as the disease progresses. The consistency and reliability of professional care allow individuals to maintain a sense of control and routine, which is especially important for people with Parkinson's who thrive on structure. For families in Prince William County and surrounding communities, Visiting Angels Manassas is a trusted provider of in-home care services for seniors with Parkinson's disease. Their caregivers are specially trained to handle the unique needs of individuals facing mobility challenges, communication difficulties, and emotional changes associated with the condition. Services offered include: Mobility and transfer assistance Medication reminders Personal hygiene and grooming support Meal preparation and light housekeeping Emotional support and companionship Visiting Angels Manassas develops customized care plans tailored to each client's stage of Parkinson's and personal preferences. By promoting safety, routine, and emotional well-being, they help individuals remain in the comfort of their own homes while receiving professional, compassionate care. While physical symptoms often take center stage, emotional health plays a critical role in daily living for people with Parkinson's. Many experience depression, anxiety, or frustration as they lose independence and struggle to perform everyday tasks. Caregivers can help by offering companionship, engaging conversation, and encouragement throughout the day. They may also guide clients through light cognitive activities such as puzzles, reading or therapy that stimulate the brain and provide mental engagement. This emotional support not only improves mood but can also slow cognitive decline and promote a more positive outlook. aring for a loved one with Parkinson's is often a full-time responsibility. The physical demands, emotional stress, and unpredictability of symptoms can quickly lead to caregiver burnout. This can compromise not only the caregiver's well-being but also the quality of care they're able to provide. Professional home care offers families much-needed relief. Whether through daily visits or occasional respite care, trained caregivers allow family members time to rest, attend to personal matters, or simply recharge. This shared responsibility ensures long-term sustainability of care and helps preserve strong family relationships. Care providers also offer education and guidance, helping families better understand Parkinson's progression and how to communicate effectively with their loved one. Specialized home care for people with Parkinson's is about more than just physical help it's about preserving independence, promoting dignity, and maintaining quality of life at every stage of the disease. With expert assistance, individuals can remain safe and supported in the comfort of their own home while families gain peace of mind. From managing medications and improving mobility to offering emotional support and caregiver relief, Parkinson's home care covers all the key areas needed for a better daily life. For families in Prince William County and nearby areas, Visiting Angels provides the personalized, reliable care needed to face Parkinson's with confidence. TIME BUSINESS NEWS
Yahoo
05-06-2025
- Health
- Yahoo
Small but 'life-changing' policy helps Parkinson's patients who need emergency care at Guelph's hospital
When people go to the emergency department, they're not allowed to take their own medications while they wait, which Theresa Daly says can be a huge problem for people with Parkinson's. A long-time nurse and social worker who actively works in Parkinson's disease support groups, Daly says she's thrilled the hospital in Guelph, Ont., has recently made a tweak to a long-standing practice to make it easier for Parkinson's patients to take their medications on time. "It's life-changing," Daly said. "Life-giving and life-saving and certainly quality of life saving." Hospitals have a policy that any medication given while a person is in the hospital must be through the pharmacy or a physicians order. Hospitals will monitor every patient's medication to avoid mixing, doubling up, choking or even overdosing. But emergency departments can be very busy and this can lead to people not getting medications on time. One of the more common medications for Parkinson's is Levodopa, used to control some of the physical deterioration symptoms. Daly says when a dose is missed, it can lead to people not feeling "normal" again for days, weeks or even months afterwards. The new policy at Guelph General Hospital says, an emergency department nurse is able to give permission to those with Parkinson's to take the medication they brought from home. Daly volunteers with the southwestern Ontario branch of Parkinson Canada and her brother also has the disease. She says she's very familiar with the toll the conditions take on both a sufferer and their loved ones. "To see them move into suffering because they haven't had their medication on time affects two people. The person with Parkinson's and the one who loves them. So it's a big deal," Daly said. Parkinson's disease is a neurological and degenerative condition. It has no cure and can get worse over time. The most commonly known issues from PD include slowness of movement, rigidity, tremors and instability. There are other symptoms associated with the condition including insomnia, anxiety, depression, bladder issues, faintness, leg swelling, heavy sweating, double vision and a multitude of other challenges. Ian Smith has Parkinson's and in the past few months, he's had to go to Guelph General Hospital three times. "[Parkinson's patients] all have different problems, some more than others ... and generally, hospitals don't like you bringing your own pills in," he said. While Smith doesn't always feel drastic effects if he misses a pill, he's familiar with how demanding the medication schedule can be. He takes three pills a day with specific food and timing restrictions. "My little Parkinson pill isn't high on the priority list because nobody has told them that it should be," Smith said. By allowing Parkinson's patients to monitor their medication, he said it's less stress for both them and, he assumes, the medical professionals. Andrea de Jong is the director of the emergency department Guelph General Hospital hospital. She said it's become a successful best practice to give emergency room nurses the power and knowledge to administer medications without having to get an order from a physician. She said there are still restrictions on who is able to administer Parkinson's medication that's brought in from home, but nurses are very familiar with these guidelines. "This ideally helps them go back home quicker and overall have a better experience here," she said. Daly said that Guelph General Hospital was very quick to approve this directive with their emergency department teams and medical advisory committee and said it's in line with much of the work Parkinson Canada aims to do within hospitals. A patient's knowledge of their own rights and their ability to advocate is a separate hurdle, she said. "There's a double prong education piece to this... people with Parkinson's have to know that it was okay, and emerge has to know that they have Parkinson's and that it's important they get their pills on time," Daly said. Parkinson Canada spokesperson Emma Gostovic told CBC News that the organization wasn't aware of any other hospitals in the country with a similar directive for Parkinson's patients and their medications. Most hospitals are still aware this is a concern and are conscious of medication timing, she said. Gostovic called Guelph General Hospital's model one they'd like to "explore and share with others throughout the clinical community."
Yahoo
29-05-2025
- Business
- Yahoo
INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy
INBRIJA, a dopamine replacement therapy for off periods in Parkinson's disease, holds significant market potential due to its ability to provide rapid relief from motor symptoms. With the increasing prevalence of Parkinson's globally, the demand for effective treatments is growing. INBRIJA offers a novel, non-oral alternative, positioning it well in the market for patients who struggle with traditional therapies. LAS VEGAS, May 29, 2025 /PRNewswire/ -- DelveInsight's "INBRIJA Market Size, Forecast, and Market Insight Report" highlights the details around INBRIJA, which consists of a dry powder formulation of levodopa for oral inhalation with the INBRIJA inhaler. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of INBRIJA. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Acorda Therapeutics' INBRIJA (Levodopa) Overview INBRIJA is an inhalable dry powder formulation of levodopa designed for use with the INBRIJA inhaler. The medication is delivered via white hypromellose capsules, each containing 42 mg of levodopa in a spray-dried powder form, along with excipients such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and sodium chloride. Levodopa, the active ingredient in INBRIJA, is an aromatic amino acid with the chemical name (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid. Its molecular formula is C₉H₁₁NO₄, and it has a molecular weight of 197.19 g/mol. INBRIJA is indicated for the intermittent relief of OFF episodes in patients with Parkinson's disease who are already receiving treatment with carbidopa/levodopa. It is not intended to replace regular carbidopa/levodopa therapy but is used to reduce OFF periods and improve motor symptoms. Each therapeutic capsule is used with a specially designed plastic inhaler featuring a blue body, blue cap, and a white mouthpiece. Patients may use INBRIJA up to five times per day, with the maximum daily dose limited to 420 mg. Drug Name INBRIJA (Levodopa) Developer Acorda Therapeutics Approval Year 2018 (US); 2019 (EU) Primary Indication Parkinson's disease Mechanism of action Dopamine receptor agonist Route of administration Oral inhalation Learn more about INBRIJA projected market size for Parkinson's disease @ INBRIJA Market Potential Parkinson's disease is a chronic and progressive neurological condition that primarily affects the ability to control movement. It is caused by the gradual loss of dopamine-producing neurons in the brain, particularly in the substantia nigra—a region vital for regulating voluntary muscle activity. According to DelveInsight, there were approximately 3 million diagnosed prevalent cases of Parkinson's disease across the 7MM in 2024, with the United States accounting for about 45% of these. Although there is currently no cure, symptom management involves a mix of medications and supportive therapies. Treatment typically includes physical, occupational, and speech therapy, and certain patients may benefit from surgical interventions. Complementary therapies are also sometimes used to help manage specific symptoms. Commonly used drugs for Parkinson's include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2A receptor antagonists. These medications primarily aim to alleviate motor symptoms, which significantly impact patients' quality of life. DelveInsight estimates the Parkinson's disease market in the 7MM to have been worth USD 3.5 billion in 2024. DelveInsight's analysis forecasts market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2020–2034). The anticipated increase in market size is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies. Discover more about the Parkinson's disease market in detail @ Parkinson's Disease Market Report Emerging Competitors of INBRIJA Some of the emerging competitors to INBRIJA in the Parkinson's disease treatment landscape include Solengepras (Cerevance), Buntanetap (Annovis Bio), Prasinezumab (Roche/Protherna), JOTROL (Jupiter Neurosciences), Glovadalen (UCB Biopharma), and others. In April 2025, Cerevance reported that the pivotal Phase III ARISE trial evaluating Solengepras as an adjunctive treatment for Parkinson's disease was ongoing, with topline results expected in the first half of 2026. Cerevance's GPR6 antagonist, Solengepras, did not meet its primary endpoint in the Phase II ASCEND trial as a monotherapy for early, untreated Parkinson's disease patients, demonstrating only a modest and statistically non-significant improvement compared to placebo, as reported at AD/PD 2025. According to the results presented at AD/PD 2025, Buntanetap has been shown to prevent cognitive decline across the entire treated ITT population. In patients with existing cognitive impairment, it improved cognitive performance along with MDS-UPDRS, WAIS, and CGI-S scores. A meeting with the US FDA to discuss the future development strategy is scheduled for the second Quarter of 2025. The ATLANTIS Phase II trial design for glovadalen was presented at AD/PD 2025, highlighting its potential as a Parkinson's treatment. As a D1PAM, it boosts dopamine signaling without directly activating receptors. To know more about the number of competing drugs in development, visit @ INBRIJA Market Positioning Compared to Other Drugs Key Milestones of INBRIJA In March 2023, Acorda Therapeutics announced that Esteve Pharmaceuticals launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. Esteve launched INBRIJA in Germany in mid-2022. In September 2019, Acorda Therapeutics announced that the European Commission (EC) granted marketing authorization for INBRIJA 33 mg inhalation powder, hard capsules. In Europe, INBRIJA is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor. The Marketing Authorization approves INBRIJA for use in the 28 countries of the European Union, as well as Iceland, Norway, and Liechtenstein. In December 2018, INBRIJA was approved by the US FDA for intermittent treatment of OFF Episodes in people with Parkinson's taking carbidopa/levodopa. Discover how INBRIJA is shaping the Parkinson's disease treatment landscape @ INBRIJA Inhaler INBRIJA Market Dynamics INBRIJA is a medication used to manage "off" periods in patients with Parkinson's disease who are on a stable regimen of oral levodopa. The market dynamics surrounding INBRIJA are influenced by several factors, including the growing demand for innovative treatments for Parkinson's disease, an aging global population, and the increasing recognition of the importance of managing off periods in patients with Parkinson's. As the number of Parkinson's disease patients continues to rise globally, particularly with the aging Baby Boomer generation, the market for Parkinson's disease therapies is expanding, offering significant growth potential for medications like INBRIJA. One of the key drivers for INBRIJA's market is the unmet need for effective treatments for off periods. Traditional oral levodopa, the mainstay of Parkinson's treatment, can lose efficacy over time, leading to motor fluctuations that result in off periods, during which patients experience a worsening of symptoms such as tremors and rigidity. INBRIJA provides an alternative in the form of an inhaled levodopa treatment that acts rapidly to help manage these periods, offering patients a faster-acting option compared to oral medications. This positioning appeals to both patients and healthcare providers who are looking for ways to improve the quality of life for people with Parkinson's. Despite its promising potential, INBRIJA faces challenges in the market. The primary hurdle is its relatively high cost compared to traditional levodopa treatments, which could limit its accessibility, particularly in regions with limited healthcare resources. Additionally, the need for an inhaler device and potential issues related to device handling and patient compliance could also impact market penetration. Moreover, INBRIJA competes with other therapeutic options in the Parkinson's space, including dopamine agonists and other adjunctive treatments, which means ongoing education and marketing efforts are required to differentiate its unique benefits. In terms of market opportunities, INBRIJA could benefit from increased awareness among healthcare providers about the drug's role in improving patient outcomes during off periods. Collaborations with Parkinson's disease advocacy groups and patient education initiatives could help drive adoption. Furthermore, expanding indications or seeking approval for additional uses could open up new revenue streams and bolster INBRIJA's position in the Parkinson's treatment market. Overall, while the market for INBRIJA faces challenges, the growing demand for better management of Parkinson's symptoms presents opportunities for continued growth and adoption. Dive deeper to get more insight into INBRIJA's strengths & weaknesses relative to competitors @ INBRIJA Market Drug Report Table of Contents 1 Report Introduction 2 INBRIJA: Acorda Therapeutics 2.1 Product Overview 2.2 Other Development Activities 2.3 Clinical Development 2.4 Clinical Trials Information 2.5 Safety and Efficacy 2.6 Product Profile 2.7 Market Assessment 2.7.1 The 7MM Analysis 2.7.1.1 Cost Assumptions and Rebate 2.7.1.2 Pricing Trends 2.7.1.3 Analogue Assessment 2.7.1.4 Launch Year and Therapy Uptake 2.7.2 The United States Market Analysis 2.7.3 EU4 and the United Kingdom Market Analysis 2.7.3.1 Germany 2.7.3.2 France 2.7.3.3 Italy 2.7.3.4 Spain 2.7.3.5 UK 2.7.4 Japan Market Analysis 2.8 Market Drivers 2.9 Market Barriers 2.10 SWOT Analysis 3 Key Cross of Marketed Competitors of INBRIJA 4 Key Cross of Emerging Competitors of INBRIJA Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, Cerevance, among others. Parkinson's Disease Pipeline Parkinson's Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others. Cell and Gene Therapy in Parkinson's Disease Market Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy in Parkinson's disease companies including MeiraGTx, Hope Biosciences, Sumitomo Pharma, Prevail Therapeutics, BlueRock Therapeutics, Voyager Therapeutics, among others. Parkinson's Disease Psychosis Market Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease psychosis companies, including Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Sign in to access your portfolio
